Gold X2 Mining Inc. (TSXV: AUXX) (OTCQB: GSHRF) (FSE: DF8) (“Gold X2” or the “Company”) is pleased to announce a significant update ...

Q3 2025 Management View Executive Chairman Ronald Williams stated, "For the third quarter, we reported revenue of $1.44 billion, medical margin of negative $57 million and adjusted EBITDA of negative ...

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week ...

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...

WillScot will host a conference call and webcast to discuss its third quarter 2025 results and 2025 outlook at 5:30 p.m. Eastern Time on Thursday, November 6, 2025. To access the live call by phone, ...

For applicants with a patent application having, or amended to have, a streamlined claim set—one independent claim and a ...

With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...

At NAACOS meeting, Bluestone ACO’s Nate Hunkins, M.P.H., described how GUIDE care navigators are complementing its advanced ...